Skip to content

Author

Elena Moreno-Caño

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Ex vivo JAK and TNF inhibitor–modulated immune signatures guide first-line therapy selection in rheumatoid arthritis

Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease for which selecting the most appropriate first targeted therapy remains challenging. We integrated ex vivo immune-cell functional assays, targeted proteomics, clinical outcomes, and a three-dimensional (3D) synovial model to identify treatment-associated m...

Sagrario Corrales, C. Pérez-Sánchez, T. Cerdó et al. · 0 citations
Open access Sep 2026

Effectiveness and retention of certolizumab pegol and JAK inhibitors in rheumatoid arthritis: a multicenter retrospective study stratified by rheumatoid factor status

Background Patients with rheumatoid arthritis (RA) and high levels of Rheumatoid Factor (RF) often present with a higher inflammatory burden and may show a reduced response to JAK inhibitors (JAKi). However, previous studies have demonstrated that certolizumab pegol (CZP) provides comparable efficacy in patients regard...

M. Parra-Moreno, Lourdes Ladehesa-Pineda, J. Calvo-Gutiérrez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.